Researchers Receive $2.5 Million Grant to Study Appendiceal Cancer
Researchers at Atrium Health Wake Forest Baptist’s NCI-designated Comprehensive Cancer Center hope to expand treatment options for appendiceal cancer with support from a $2.5 million grant from the National Cancer Institute.
Personalized Immunotherapy Response Studied in Body-on-a-Chip Cancer Models
Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people. Immunotherapies, also known as biologic therapies, activate the body’s own immune system to control, and eliminate cancer.
The Wake Forest Comprehensive Cancer Center (WFORCE) is announcing three immune-oncology faculty positions for experts with peer reviewed funding and a strong vision in developing research tools for direct clinical application. The candidates should have a proven record in the fields of adaptive immunity, CAR T-cells and immunotherapy. Required is a PhD or MD degree and a focus on bench to bedside translational applications. Applicants must be U.S. citizen, permanent resident or have a valid working visa and be currently located in the US.
Interested candidates should submit their CV/resume to email@example.com and firstname.lastname@example.org
Appendiceal Cancer, Melanoma and HIPEC Organoid manuscripts by WFORCE all featured in Influential Articles in Surgical Oncology
Wake Forest Baptist Health Researchers Awarded $2.5 Million Grant
Wake Forest Baptist Health has received a $2.5 million award to study treatment options for aggressive cancers. The National Cancer Institute grant will support ongoing studies at Wake’s Organoid Research Center — a joint effort between the Cancer Center and Institute for Regenerative Medicine. Source: WFDD
$2.5M Award to Fund Joint Organoid Research Program at Wake Forest Baptist Health to Treat Aggressive Cancers
The Wake Forest Organoid Research Center (WFORCE) is a joint effort between the Wake Forest Baptist Comprehensive Cancer Center and the Wake Forest Institute for Regenerative Medicine (WFIRM) to tailor personalized therapy for patients.
Mesothelioma organoid manuscript included in Editor's choice and Top 100 in Cell and Molecular Biology by Scientific Reports